
News|Videos|August 15, 2023
Recent Progress and Unmet Needs in NSCLC
Author(s)Joshua K. Sabari, MD, Narjust Florez, MD
Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5





























